NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

马萨诸塞州剑桥市 - 市值5,931万美元的临床阶段肿瘤公司Immuneering Corporation (NASDAQ: IMRX )与Regeneron制药公司达成临床供应协议，评估其主要产品候选药物IMM-1-104与Regeneron的抗PD-1疗法Libtayo（cemiplimab）的联合用药潜力。根据 InvestingPro ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

The pharma world , esp the big boys dont play clean .. IMM have now done their job and its now down to a big boys to finish it or delay it .. The conference would have been the place to close the deal ...

IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...

(1) when that person’s mother was unlawfully present in the United States and the person’s father was not a United States citizen or lawful permanent resident at the time of said person’s ...

生物制药公司Immuneering Corp (NASDAQ:IMRX)市值为6334万美元，该公司宣布其正在进行的IMM-1-104治疗晚期RAS突变实体瘤的2a期临床试验中期数据令人鼓舞。 根据InvestingPro分析，该公司保持强劲的流动性，流动比率为7.99，尽管面临显著的现金消耗挑战。今天，公司披露该 ...

Copyright 2025 The Associated Press. All Rights Reserved. Toronto Raptors forward Scottie Barnes (4) and Golden State Warriors forward Gui Santos (15) vie for control ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated ...